Sunitinib paves the way for targeted therapies in neuroendocrine tumors. [electronic resource]
Producer: 20100430Description: 253-4 p. digitalISSN:- 1776-260X
- Angiogenesis Inhibitors -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor
- Carcinoid Tumor -- drug therapy
- Cell Line, Tumor
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- ErbB Receptors -- therapeutic use
- Humans
- Indoles -- therapeutic use
- Kidney Neoplasms -- drug therapy
- Lung Neoplasms -- drug therapy
- Melphalan -- therapeutic use
- Neovascularization, Pathologic -- prevention & control
- Neuroendocrine Tumors -- drug therapy
- Pancreatic Neoplasms -- drug therapy
- Procarbazine -- therapeutic use
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins c-kit
- Pyrroles -- therapeutic use
- Sunitinib
- Vinblastine -- therapeutic use
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.